SEC Comment Letter for NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735) (NYMXF) — Dec 22, 2021
NYMOX PHARMACEUTICAL CORP (NYMXF) (CIK 0001018735)
Date: Dec. 22, 2021 · CIK: 0001018735 · Accession: 0000000000-21-015284
AI Filing Summary & Sentiment
File numbers found in text: 333-261571
Letter
United States securities and exchange commission logo December 22, 2021 Paul Averback Chief Executive Officer NYMOX PHARMACEUTICAL CORP Bay & Deveaux Streets Nassau, The Bahamas Re:NYMOX PHARMACEUTICAL CORP Registration Statement on Form F-3 Filed December 9, 2021 File No. 333-261571 Dear Dr. Averback: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Richard Cutler, Esq.
Show Raw Text
United States securities and exchange commission logo
December 22, 2021
Paul Averback
Chief Executive Officer
NYMOX PHARMACEUTICAL CORP
Bay & Deveaux Streets
Nassau, The Bahamas
Re:NYMOX PHARMACEUTICAL CORP
Registration Statement on Form F-3
Filed December 9, 2021
File No. 333-261571
Dear Dr. Averback:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Richard Cutler, Esq.